UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Newspaper Article (24336) 24336
Journal Article (14695) 14695
Magazine Article (3420) 3420
Government Document (2502) 2502
Report (2498) 2498
Web Resource (1874) 1874
Trade Publication Article (1631) 1631
Newsletter (1079) 1079
Transcript (690) 690
Book / eBook (341) 341
Book Chapter (243) 243
Reference (110) 110
Dissertation (109) 109
Book Review (59) 59
Paper (57) 57
Data Set (37) 37
Conference Proceeding (22) 22
Journal / eJournal (7) 7
Publication (7) 7
Market Research (4) 4
Streaming Video (4) 4
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
health insurance (16463) 16463
insurance industry (10919) 10919
pharmaceutical industry (9842) 9842
humans (8250) 8250
medicare (7000) 7000
science & technology (6891) 6891
life sciences & biomedicine (6554) 6554
health care policy (6353) 6353
insurance coverage (5752) 5752
united states (5376) 5376
health care industry (4347) 4347
insurance (4077) 4077
drugs (3979) 3979
earnings per share (3923) 3923
health insurance industry (3846) 3846
prescription drugs (3492) 3492
medicaid (3379) 3379
hospitals (3160) 3160
health care sciences & services (3026) 3026
stockholders (2926) 2926
female (2921) 2921
investments (2861) 2861
health care expenditures (2773) 2773
corporate profits (2722) 2722
male (2715) 2715
cost control (2708) 2708
aged (2631) 2631
public health (2580) 2580
health policy & services (2458) 2458
dividends (2394) 2394
studies (2382) 2382
life insurance (2305) 2305
research (2288) 2288
health care (2256) 2256
patients (2189) 2189
economics (2158) 2158
group insurance (2156) 2156
stock exchanges (2152) 2152
financial institutions (2122) 2122
costs (2118) 2118
health administration (2106) 2106
medicine (2104) 2104
middle aged (2016) 2016
physicians (1999) 1999
corporate profiles (1984) 1984
health services (1941) 1941
social sciences (1929) 1929
consumers (1915) 1915
laws, regulations and rules (1871) 1871
analysis (1845) 1845
insurance companies (1839) 1839
adult (1838) 1838
insurance, pharmaceutical services (1781) 1781
employment (1756) 1756
medical care, cost of (1751) 1751
liability insurance (1723) 1723
pharmaceuticals (1710) 1710
economic policy (1703) 1703
pharmacy (1672) 1672
medical research (1634) 1634
contracts (1600) 1600
national health insurance (1592) 1592
small business (1571) 1571
health care reform (1539) 1539
drug stores (1537) 1537
poverty (1525) 1525
statistical data (1520) 1520
banking industry (1510) 1510
education (1508) 1508
insurance policies (1491) 1491
swot analysis (1439) 1439
patient protection & affordable care act 2010-us (1431) 1431
older people (1416) 1416
women (1415) 1415
government (1392) 1392
senate (1392) 1392
economic aspects (1388) 1388
employers (1387) 1387
congressional committees (1386) 1386
taxation (1385) 1385
veterans (1383) 1383
congress (1379) 1379
social security (1377) 1377
federal employees (1364) 1364
international relations (1361) 1361
department of defense (1358) 1358
insurance, pharmaceutical services - economics (1352) 1352
house of representatives (1350) 1350
health (1347) 1347
capital gains (1317) 1317
medical personnel (1302) 1302
institutional investments (1292) 1292
health economics (1290) 1290
equity (1274) 1274
prices (1274) 1274
employees (1266) 1266
management (1259) 1259
california (1247) 1247
energy resources (1241) 1241
civil liberties (1230) 1230
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (246) 246
Robarts - Government Pubs (123) 123
Gerstein Science - Stacks (115) 115
UofT at Scarborough - Stacks (26) 26
Collection Dvlpm't (Acquisitions) - Vendor file (22) 22
Robarts - Stacks (22) 22
UofT at Mississauga - Stacks (18) 18
UTL at Downsview - May be requested (9) 9
Law (Bora Laskin) - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Gerstein Science - Periodical Stacks (5) 5
St. Michael's College (John M. Kelly) - 2nd Floor (4) 4
New College (Ivey) - Stacks (3) 3
University College (Laidlaw) - Stacks (3) 3
Gerstein Science - Circulation Desk (2) 2
OISE - Stacks (2) 2
Toronto East General Hospital - Stacks (2) 2
Business (Joseph L Rotman) - Missing (1) 1
Credit Valley Hospital - Stacks (1) 1
Criminology - Stacks (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Dentistry (Harry R Abbott) - Withdrawn (1) 1
Gerstein Science - Bindery (1) 1
Gerstein Science - Library use only (1) 1
Gerstein Science - May be requested (1) 1
Gerstein Science - Theses (1) 1
Humber River Regional Hospital - Departmental Serials (1) 1
Media Commons - Audio Visual (1) 1
Online Resources - Pharmacy (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Processing (1) 1
Scarborough Hospital - General (1) 1
St. Augustine's Seminary - Stacks (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Periodicals (1) 1
UofT at Scarborough - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (53309) 53309
French (142) 142
German (127) 127
Spanish (100) 100
Portuguese (51) 51
Japanese (32) 32
Italian (14) 14
Swedish (13) 13
Polish (10) 10
Danish (8) 8
Norwegian (8) 8
Chinese (7) 7
Russian (7) 7
Tagalog (7) 7
Haitian (6) 6
Hebrew (5) 5
Vietnamese (5) 5
Dutch (4) 4
Hungarian (4) 4
Korean (4) 4
Czech (3) 3
Greek (3) 3
Armenian (2) 2
Indonesian (2) 2
Persian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Finnish (1) 1
Hindi (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2015, Studies in comparative political economy and public policy, ISBN 9781442648630, Volume 48, x, 217
Book
2002, World Bank discussion paper, ISBN 0821352121, Volume no. 437., xiii, 59 p. cm.
This report assesses the pharmaceutical sector in India, particularly focusing on four key issues related to the production, procurement, and distribution of drugs in India: a) availability, b) affordability; c) quality, and d... 
Drugs | Pharmaceutical policy | Pharmaceutical industry | Marketing | INFORMAL SECTOR | PHARMACY | PHARMACEUTICAL SERVICES | PHARMACEUTICAL MANUFACTURERS | PHYSICIANS | MEDICINAL DRUGS | DRUG UTILIZATION | DEVELOPED COUNTRIES | PHARMACISTS | HEALTH SECTOR | HUMAN DEVELOPMENT | PILL | VACCINES | NATIONAL DRUG POLICIES | NATIONAL DRUG POLICY | PRIVATE SECTOR | QUALITY CONTROL | GMP | LAWS | DISTRIBUTION OF PHARMACEUTICALS | PHARMACEUTICAL SUPPLY | NUTRITION | HEALTH CARE FINANCING | ADVERSE EFFECTS | PHARMACY CURRICULA | HOSPITALS | PHARMACEUTICAL COMPANIES | PHARMACEUTICAL POLICY | INCOME | DRUGS | INTERNATIONAL TRADE ACCOUNTING | NDP | HEALTH POLICY | TREATMENT GUIDELINES | THERAPEUTICS | PHARMACEUTICALS | PRODUCERS | MARKETING | PUBLIC EDUCATION | AVAILABILITY | PATENTS | SOCIAL SERVICES | SAFETY NETS | PHARMACEUTICALS PROCUREMENT | PUBLIC SECTOR | SAFETY | SANCTIONS | IRRATIONAL USE | ADVERTISING | INNOVATION | MEDICINES | PHARMACEUTICAL POLICIES | PHARMACEUTICAL SECTOR | DRUG LAW | DRUG INDUSTRY | PHARMACEUTICAL QUALITY ASSURANCE | DISCRIMINATION | GOVERNMENT REGULATIONS | GENERIC DRUGS | LOCAL PRODUCTION | PHARMACY SCHOOLS | PHARMACEUTICAL PATENTS | DRUG SELECTION | PHARMACEUTICAL RESEARCH | NURSING | DRUG PRICES | PHARMACEUTICAL QUALITY | AFFORDABILITY | TELECOMMUNICATIONS | COST SAVINGS | OIL | RATIONAL USE OF DRUGS | MEDICATION | INSURANCE | CERTIFICATION | DRUG CONTROL | PROCUREMENT | SOCIAL INSURANCE | MINISTRIES OF HEALTH | HUMAN BEHAVIOUR | PROPERTY RIGHTS | EXPENDITURES | IMPORTS | GENERIC SUBSTITUTION | BRAND NAME DRUGS | GOOD MANUFACTURING PRACTICES | HEALTH CARE SERVICES | LABORATORIES | PURCHASING | POLICY INSTRUMENTS | PHARMACEUTICAL INDUSTRY | SUSTAINABLE DEVELOPMENT | HEALTH CARE | ESSENTIAL DRUGS | ECONOMICS | HEALTH CARE COSTS | CONTRACTING OUT
Book
2010, 1, ISBN 9780520262386, xii, 168
Daniel M. Fox gives an incisive assessment of the critical collaboration between researchers and public officials that has recently emerged to evaluate the effectiveness and comparative effectiveness of health services... 
Medical policy | History, 20th century | United States | History | Health services research | Insurance, pharmaceutical services | Health policy | Pharmaceutical policy | Government programs | Politics | History, 21st century | National Health Services | Health Sciences | Health Policy | MEDICAL | National health services
Book
2010, Directions in development. Human development, ISBN 9780821383865, xxi, 215
Pharmaceuticals are an essential component of health care. But for many people in low- and middle-income countries, access to the medicines they need to prevent or treat severe illnesses is limited... 
economics | Developed Countries | Health Plan Implementation | Pharmaceutical policy | Drug Industry | Government Regulation | Health Policy | organization & administration | Medical policy | PHARMACY | INDUSTRIAL DEVELOPMENT | REGULATORY BARRIERS | SERVICE DELIVERY | PHYSICIANS | INTERNATIONAL AGREEMENTS | CITIZENSHIP | FIXED COSTS | HEALTH SECTOR | ABUSE | HUMAN DEVELOPMENT | PHARMACEUTICAL REGULATION | SUPPLY CHAIN | UNEMPLOYMENT RATES | ECONOMIC GROWTH | RETAIL PHARMACIES | GOOD GOVERNANCE | POLICY FRAMEWORK | PRIVATE PHARMACIES | PHARMACEUTICAL PROCUREMENT | PUBLIC POLICY | PRICE REGULATION | DIABETES | MEDICAL SUPPLIES | GMP | HEALTH SYSTEMS | BRIBERY | HEALTH WORKERS | PAYMENT TERMS | HEALTH SERVICES | MALARIA | PHARMACEUTICAL SUPPLY | HIGH BLOOD PRESSURE | TECHNICAL CAPACITY | MORTALITY | PATIENTS | FRAUD | BIOLOGICALS | CAPSULES | TUBERCULOSIS | HOSPITALS | NARCOTICS | SUPPLIER | DEVELOPING COUNTRIES | PHARMACEUTICAL POLICY | ACCOUNTABILITY | DECISION MAKING | HOME COUNTRIES | SALES | HEALTH POLICY | TURNOVER | TRANSPORTATION | DEMOCRACY | DOSAGE FORMS | MARKETING | HEALTH INSURANCE | MEDICAL SPECIALISTS | CHRONIC DISEASES | CLINICS | EDUCATION SYSTEMS | CENTRAL MEDICAL STORES | STOCKS | PURCHASING POWER | HEALTH OUTCOMES | REFORM EFFORT | COMPETITIVE BIDDING | MEDICINES | NATIONAL DRUG | CANCER | PHARMACEUTICAL POLICIES | NURSE | TABLETS | HEALTH CARE PROVIDERS | DRUG INDUSTRY | INVENTORY | DISCRIMINATION | DISTRIBUTION SYSTEMS | FAMILIES | CIVIL SOCIETY ORGANIZATIONS | DISABILITY | COMPLICATIONS | FAMILY MEMBERS | WHOLESALERS | CIF | DRUG PRICES | HEALTH SYSTEM | NATIONAL GOVERNMENT | CONSUMER GROUPS | BRAND | HUMAN IMMUNODEFICIENCY VIRUS | MEDICAL EDUCATION | MARKET ENTRY | HOSPITAL | OPERATING COSTS | CHEMISTS | SUPPLIERS | UNIVERSAL ACCESS | QUALITY ASSURANCE | LOCAL ECONOMY | ILLNESS | PROCUREMENT | RURAL AREAS | MEDICINE | GLOBAL DEVELOPMENT | REGULATORY AGENCIES | IMMUNIZATION | INDUSTRIAL PRODUCTION | CARDIOVASCULAR DISEASE | ENVIRONMENTAL PROTECTION | PROGRESS | URBAN POPULATION | GLOBAL POLICY | GOOD MANUFACTURING PRACTICES | INFORMATION SYSTEMS | LABORATORIES | DOMESTIC MANUFACTURERS | WORLD HEALTH ORGANIZATION | PACKAGING | RETAIL | CLINICAL TRIALS | POOLED PROCUREMENT | ACQUIRED IMMUNODEFICIENCY SYNDROME | POLITICAL DECISION | INTERMEDIARIES | HEALTH CARE | HEALTH CARE ACCESS | COMPETITIVENESS | PHARMACEUTICAL MANUFACTURERS | INVENTORY MANAGEMENT | CORRUPTION | PHARMACEUTICAL EXPENDITURE | CITIZENS | POLITICAL OPPOSITION | PRACTITIONERS | PHARMACISTS | LOW-INCOME COUNTRY | MEDICAL SCHOOL | NURSES | VACCINES | MEDICAL SERVICES | QUANTITATIVE DATA | WORKERS | NATIONAL LEGISLATION | QUALITY CONTROL | DEVELOPMENT GOALS | LAWS | PHARMACEUTICAL PRODUCTS | HEALTH CARE REFORM | MINISTRY OF HEALTH | DISSEMINATION | TRADE ISSUES | NUTRITION | POLITICAL SUPPORT | POLICY GOALS | PRESCRIPTIONS | USE OF RESOURCES | HEALTH CARE SYSTEM | PUBLIC HEALTH | RISK FACTORS | DEVELOPMENT POLICY | PUBLIC SUPPORT | PHARMACEUTICAL COMPANIES | PHARMACEUTICAL REFORM | LOCAL MANUFACTURERS | DRUGS | HEALTH MANAGEMENT | PHARMACEUTICALS | PHARMACEUTICAL MARKETS | PHARMACEUTICAL ¸ MANUFACTURERS | SERVICE QUALITY | HEALTH POLICIES | DEATH RATES | MANAGEMENT SYSTEMS | HIV | DRUG DONATIONS | LEGAL STATUS | MILLENNIUM DEVELOPMENT GOALS | PATIENT | HEALTH CENTERS | COMMODITIES | ESSENTIAL MEDICINES | MEDICAL NEEDS | PHARMACEUTICAL | IMPORTED DRUGS | PHARMACEUTICAL SECTOR | SUPPLY CHAINS | RESPECT | PERSONAL RELATIONSHIPS | POLICY DECISIONS | LIFE EXPECTANCY | GENERIC DRUGS | PHARMACOLOGISTS | LOW-INCOME COUNTRIES | WAREHOUSE | PHARMACIES | FUTURE GROWTH | PHARMACEUTICAL MARKETING | EMERGING MARKETS | RATIONAL USE OF DRUGS | HEALTH REFORM | IMMUNODEFICIENCY | SOCIAL SECURITY | DELIVERY SYSTEMS | FAVORITISM | DRUG CONTROL | INTERNATIONAL ORGANIZATIONS | SECURE SUPPLY | ILLNESSES | QUALITY OF CARE | CHILD MORTALITY | REGULATORY AUTHORITIES | MINISTRIES OF HEALTH | HEALTH FACILITIES | DONOR FINANCING | PHARMACEUTICAL PRICING | PURCHASING | UNEMPLOYMENT | GOVERNMENT AGENCIES | PHARMACEUTICAL INDUSTRY | PUBLIC HEALTH POLICY | POLICY MAKERS | WAREHOUSES | PHARMACEUTICAL PRICING POLICIES | BUDGETING | POLITICAL CHANGE | ESSENTIAL DRUGS | SERVICE PROVIDERS
Book
1995, 2nd ed., ISBN 1560249560, xix, 221 p. :ill.
Book
2004, ISBN 0821358480, xxv, 152
...) and associated health services. This technical guide examines the elements required to establish and ensure continuity of supplies, including medicines and other commodities... 
drug therapy | Drug Industry | supply & distribution | Economic aspects | Anti-Retroviral Agents | HIV infections | Chemotherapy | economics | Purchasing | Pharmaceutical policy | Antiretroviral agents | Acquired Immunodeficiency Syndrome | AIDS (Disease) | Pharmaceutical industry | PHARMACEUTICAL MANUFACTURERS | DRUG RESISTANCE | ECONOMIC INCENTIVES | SERVICE DELIVERY | DEVELOPED COUNTRIES | WASTE | MORBIDITY | SOCIAL MARKETING | HUMAN DEVELOPMENT | PHARMACEUTICAL PROCUREMENT | QUALITY CONTROL | MEDICAL SUPPLIES | DRUG FORMULARY | HIV TESTING | DEVELOPMENT GOALS | ACCESS TO TREATMENT | PSYCHOSOCIAL SUPPORT | PHARMACEUTICAL PRODUCTS | HEALTH SERVICES | MALARIA | PHARMACEUTICAL SUPPLY | MORTALITY | PUBLIC HEALTH | PATIENTS | TUBERCULOSIS | ECONOMIC IMPACT | ORPHANS | AWARENESS CAMPAIGNS | PHARMACEUTICAL POLICY | LEGISLATION | ISOLATION | INCOME | DRUGS | PRODUCTION COSTS | PANDEMIC | PRODUCERS | PREVENTION OF MOTHER-TO-CHILD TRANSMISSION | HEALTH INSURANCE | EVALUATION CRITERIA | INCOME LEVELS | HIV | ADOLESCENTS | PATENTS | FINANCIAL FEASIBILITY | HIV-POSITIVE PEOPLE | CENTRAL MEDICAL STORES | COMMODITIES | VIRAL LOAD | INCIDENCE OF HIV | PUBLIC SECTOR | SAFETY | HEALTH PROBLEMS | MEDICINES | DISEASE PREVENTION | BIDDING | IMMUNE SYSTEM | FAMILIES | PEOPLE WITH HIV | ADHERENCE TO TREATMENT | GENERIC PRODUCTS | QUALITY STANDARDS | DRUG SELECTION | UNAIDS | CONDOMS | DRUG PRICES | AIDS TREATMENT | ARVS | BLOOD SAFETY | AIDS PROGRAMS | RESOURCE ALLOCATION | CRITICAL APPRAISAL | HIV TRANSMISSION | QUALITY ASSURANCE | OPPORTUNISTIC INFECTIONS | ILLNESS | PROCUREMENT | MEDICINE | AIDS ORPHANS | MALNUTRITION | ANTIRETROVIRAL DRUGS | PROPERTY RIGHTS | MOTHER-TO-CHILD | ECONOMIC CONSEQUENCES | IMPORTS | HIV PREVALENCE | HIV POSITIVE | PURCHASING | QUALITY OF LIFE | BREASTFEEDING | PROJECT IMPLEMENTATION | PALLIATIVE CARE | WORLD HEALTH ORGANIZATION | FEASIBILITY | CLINICAL TRIALS | HIV INFECTION | POOLED PROCUREMENT | TREATMENT POLICIES | COMMUNITY EDUCATION | PEOPLE WITH AIDS | BREAST MILK | HEALTH CARE | INFECTION RATES | HIV TEST
Book
2011, ISBN 082138760X, 346
...) to the performance problems of the pharmaceutical sector. The book is divided into three sections. The first section presents the basic ideas for analysis... 
Pharmaceutical policy | Pharmaceutical industry | Health care reform | PHARMACY | INDUSTRIAL DEVELOPMENT | REGULATORY BARRIERS | SERVICE DELIVERY | PHYSICIANS | INTERNATIONAL AGREEMENTS | CITIZENSHIP | FIXED COSTS | HEALTH SECTOR | ABUSE | HUMAN DEVELOPMENT | PHARMACEUTICAL REGULATION | SUPPLY CHAIN | UNEMPLOYMENT RATES | ECONOMIC GROWTH | RETAIL PHARMACIES | GOOD GOVERNANCE | POLICY FRAMEWORK | PRIVATE PHARMACIES | PHARMACEUTICAL PROCUREMENT | PUBLIC POLICY | PRICE REGULATION | DIABETES | MEDICAL SUPPLIES | GMP | HEALTH SYSTEMS | BRIBERY | HEALTH WORKERS | PAYMENT TERMS | HEALTH SERVICES | MALARIA | PHARMACEUTICAL SUPPLY | HIGH BLOOD PRESSURE | TECHNICAL CAPACITY | MORTALITY | PATIENTS | FRAUD | BIOLOGICALS | CAPSULES | TUBERCULOSIS | HOSPITALS | NARCOTICS | SUPPLIER | DEVELOPING COUNTRIES | PHARMACEUTICAL POLICY | ACCOUNTABILITY | DECISION MAKING | HOME COUNTRIES | SALES | HEALTH POLICY | TURNOVER | TRANSPORTATION | DEMOCRACY | DOSAGE FORMS | MARKETING | HEALTH INSURANCE | MEDICAL SPECIALISTS | CHRONIC DISEASES | CLINICS | EDUCATION SYSTEMS | CENTRAL MEDICAL STORES | STOCKS | PURCHASING POWER | HEALTH OUTCOMES | REFORM EFFORT | COMPETITIVE BIDDING | MEDICINES | NATIONAL DRUG | CANCER | PHARMACEUTICAL POLICIES | NURSE | TABLETS | HEALTH CARE PROVIDERS | DRUG INDUSTRY | INVENTORY | DISCRIMINATION | DISTRIBUTION SYSTEMS | FAMILIES | CIVIL SOCIETY ORGANIZATIONS | DISABILITY | COMPLICATIONS | FAMILY MEMBERS | WHOLESALERS | CIF | DRUG PRICES | HEALTH SYSTEM | NATIONAL GOVERNMENT | CONSUMER GROUPS | BRAND | HUMAN IMMUNODEFICIENCY VIRUS | MEDICAL EDUCATION | MARKET ENTRY | HOSPITAL | OPERATING COSTS | CHEMISTS | SUPPLIERS | UNIVERSAL ACCESS | QUALITY ASSURANCE | LOCAL ECONOMY | ILLNESS | PROCUREMENT | RURAL AREAS | MEDICINE | GLOBAL DEVELOPMENT | REGULATORY AGENCIES | IMMUNIZATION | INDUSTRIAL PRODUCTION | CARDIOVASCULAR DISEASE | ENVIRONMENTAL PROTECTION | PROGRESS | URBAN POPULATION | GLOBAL POLICY | GOOD MANUFACTURING PRACTICES | INFORMATION SYSTEMS | LABORATORIES | DOMESTIC MANUFACTURERS | WORLD HEALTH ORGANIZATION | PACKAGING | RETAIL | CLINICAL TRIALS | POOLED PROCUREMENT | ACQUIRED IMMUNODEFICIENCY SYNDROME | POLITICAL DECISION | INTERMEDIARIES | HEALTH CARE | HEALTH CARE ACCESS | COMPETITIVENESS | PHARMACEUTICAL MANUFACTURERS | INVENTORY MANAGEMENT | CORRUPTION | PHARMACEUTICAL EXPENDITURE | CITIZENS | POLITICAL OPPOSITION | PRACTITIONERS | PHARMACISTS | LOW-INCOME COUNTRY | MEDICAL SCHOOL | NURSES | VACCINES | MEDICAL SERVICES | QUANTITATIVE DATA | WORKERS | NATIONAL LEGISLATION | QUALITY CONTROL | DEVELOPMENT GOALS | LAWS | PHARMACEUTICAL PRODUCTS | HEALTH CARE REFORM | MINISTRY OF HEALTH | DISSEMINATION | TRADE ISSUES | NUTRITION | POLITICAL SUPPORT | POLICY GOALS | PRESCRIPTIONS | USE OF RESOURCES | HEALTH CARE SYSTEM | PUBLIC HEALTH | RISK FACTORS | DEVELOPMENT POLICY | PUBLIC SUPPORT | PHARMACEUTICAL COMPANIES | PHARMACEUTICAL REFORM | LOCAL MANUFACTURERS | DRUGS | HEALTH MANAGEMENT | PHARMACEUTICALS | PHARMACEUTICAL MARKETS | PHARMACEUTICAL ¸ MANUFACTURERS | SERVICE QUALITY | HEALTH POLICIES | DEATH RATES | MANAGEMENT SYSTEMS | HIV | DRUG DONATIONS | LEGAL STATUS | MILLENNIUM DEVELOPMENT GOALS | PATIENT | HEALTH CENTERS | COMMODITIES | ESSENTIAL MEDICINES | MEDICAL NEEDS | PHARMACEUTICAL | IMPORTED DRUGS | PHARMACEUTICAL SECTOR | SUPPLY CHAINS | RESPECT | PERSONAL RELATIONSHIPS | POLICY DECISIONS | LIFE EXPECTANCY | GENERIC DRUGS | PHARMACOLOGISTS | LOW-INCOME COUNTRIES | WAREHOUSE | PHARMACIES | FUTURE GROWTH | PHARMACEUTICAL MARKETING | EMERGING MARKETS | RATIONAL USE OF DRUGS | HEALTH REFORM | IMMUNODEFICIENCY | SOCIAL SECURITY | DELIVERY SYSTEMS | FAVORITISM | DRUG CONTROL | INTERNATIONAL ORGANIZATIONS | SECURE SUPPLY | ILLNESSES | QUALITY OF CARE | CHILD MORTALITY | REGULATORY AUTHORITIES | MINISTRIES OF HEALTH | HEALTH FACILITIES | DONOR FINANCING | PHARMACEUTICAL PRICING | PURCHASING | UNEMPLOYMENT | GOVERNMENT AGENCIES | PHARMACEUTICAL INDUSTRY | PUBLIC HEALTH POLICY | POLICY MAKERS | WAREHOUSES | PHARMACEUTICAL PRICING POLICIES | BUDGETING | POLITICAL CHANGE | ESSENTIAL DRUGS | SERVICE PROVIDERS
eBook
2011, ISBN 082138760X, 346
...) to the performance problems of the pharmaceutical sector. The book is divided into three sections. The first section presents the basic ideas for analysis... 
Pharmaceutical policy | Pharmaceutical industry | Health care reform | PHARMACY | INDUSTRIAL DEVELOPMENT | REGULATORY BARRIERS | SERVICE DELIVERY | PHYSICIANS | INTERNATIONAL AGREEMENTS | CITIZENSHIP | FIXED COSTS | HEALTH SECTOR | ABUSE | HUMAN DEVELOPMENT | PHARMACEUTICAL REGULATION | SUPPLY CHAIN | UNEMPLOYMENT RATES | ECONOMIC GROWTH | RETAIL PHARMACIES | GOOD GOVERNANCE | POLICY FRAMEWORK | PRIVATE PHARMACIES | PHARMACEUTICAL PROCUREMENT | PUBLIC POLICY | PRICE REGULATION | DIABETES | MEDICAL SUPPLIES | GMP | HEALTH SYSTEMS | BRIBERY | HEALTH WORKERS | PAYMENT TERMS | HEALTH SERVICES | MALARIA | PHARMACEUTICAL SUPPLY | HIGH BLOOD PRESSURE | TECHNICAL CAPACITY | MORTALITY | PATIENTS | FRAUD | BIOLOGICALS | CAPSULES | TUBERCULOSIS | HOSPITALS | NARCOTICS | SUPPLIER | DEVELOPING COUNTRIES | PHARMACEUTICAL POLICY | ACCOUNTABILITY | DECISION MAKING | HOME COUNTRIES | SALES | HEALTH POLICY | TURNOVER | TRANSPORTATION | DEMOCRACY | DOSAGE FORMS | MARKETING | HEALTH INSURANCE | MEDICAL SPECIALISTS | CHRONIC DISEASES | CLINICS | EDUCATION SYSTEMS | CENTRAL MEDICAL STORES | STOCKS | PURCHASING POWER | HEALTH OUTCOMES | REFORM EFFORT | COMPETITIVE BIDDING | MEDICINES | NATIONAL DRUG | CANCER | PHARMACEUTICAL POLICIES | NURSE | TABLETS | HEALTH CARE PROVIDERS | DRUG INDUSTRY | INVENTORY | DISCRIMINATION | DISTRIBUTION SYSTEMS | FAMILIES | CIVIL SOCIETY ORGANIZATIONS | DISABILITY | COMPLICATIONS | FAMILY MEMBERS | WHOLESALERS | CIF | DRUG PRICES | HEALTH SYSTEM | NATIONAL GOVERNMENT | CONSUMER GROUPS | BRAND | HUMAN IMMUNODEFICIENCY VIRUS | MEDICAL EDUCATION | MARKET ENTRY | HOSPITAL | OPERATING COSTS | CHEMISTS | SUPPLIERS | UNIVERSAL ACCESS | QUALITY ASSURANCE | LOCAL ECONOMY | ILLNESS | PROCUREMENT | RURAL AREAS | MEDICINE | GLOBAL DEVELOPMENT | REGULATORY AGENCIES | IMMUNIZATION | INDUSTRIAL PRODUCTION | CARDIOVASCULAR DISEASE | ENVIRONMENTAL PROTECTION | PROGRESS | URBAN POPULATION | GLOBAL POLICY | GOOD MANUFACTURING PRACTICES | INFORMATION SYSTEMS | LABORATORIES | DOMESTIC MANUFACTURERS | WORLD HEALTH ORGANIZATION | PACKAGING | RETAIL | CLINICAL TRIALS | POOLED PROCUREMENT | ACQUIRED IMMUNODEFICIENCY SYNDROME | POLITICAL DECISION | INTERMEDIARIES | HEALTH CARE | HEALTH CARE ACCESS | COMPETITIVENESS | PHARMACEUTICAL MANUFACTURERS | INVENTORY MANAGEMENT | CORRUPTION | PHARMACEUTICAL EXPENDITURE | CITIZENS | POLITICAL OPPOSITION | PRACTITIONERS | PHARMACISTS | LOW-INCOME COUNTRY | MEDICAL SCHOOL | NURSES | VACCINES | MEDICAL SERVICES | QUANTITATIVE DATA | WORKERS | NATIONAL LEGISLATION | QUALITY CONTROL | DEVELOPMENT GOALS | LAWS | PHARMACEUTICAL PRODUCTS | HEALTH CARE REFORM | MINISTRY OF HEALTH | DISSEMINATION | TRADE ISSUES | NUTRITION | POLITICAL SUPPORT | POLICY GOALS | PRESCRIPTIONS | USE OF RESOURCES | HEALTH CARE SYSTEM | PUBLIC HEALTH | RISK FACTORS | DEVELOPMENT POLICY | PUBLIC SUPPORT | PHARMACEUTICAL COMPANIES | PHARMACEUTICAL REFORM | LOCAL MANUFACTURERS | DRUGS | HEALTH MANAGEMENT | PHARMACEUTICALS | PHARMACEUTICAL MARKETS | PHARMACEUTICAL ¸ MANUFACTURERS | SERVICE QUALITY | HEALTH POLICIES | DEATH RATES | MANAGEMENT SYSTEMS | HIV | DRUG DONATIONS | LEGAL STATUS | MILLENNIUM DEVELOPMENT GOALS | PATIENT | HEALTH CENTERS | COMMODITIES | ESSENTIAL MEDICINES | MEDICAL NEEDS | PHARMACEUTICAL | IMPORTED DRUGS | PHARMACEUTICAL SECTOR | SUPPLY CHAINS | RESPECT | PERSONAL RELATIONSHIPS | POLICY DECISIONS | LIFE EXPECTANCY | GENERIC DRUGS | PHARMACOLOGISTS | LOW-INCOME COUNTRIES | WAREHOUSE | PHARMACIES | FUTURE GROWTH | PHARMACEUTICAL MARKETING | EMERGING MARKETS | RATIONAL USE OF DRUGS | HEALTH REFORM | IMMUNODEFICIENCY | SOCIAL SECURITY | DELIVERY SYSTEMS | FAVORITISM | DRUG CONTROL | INTERNATIONAL ORGANIZATIONS | SECURE SUPPLY | ILLNESSES | QUALITY OF CARE | CHILD MORTALITY | REGULATORY AUTHORITIES | MINISTRIES OF HEALTH | HEALTH FACILITIES | DONOR FINANCING | PHARMACEUTICAL PRICING | PURCHASING | UNEMPLOYMENT | GOVERNMENT AGENCIES | PHARMACEUTICAL INDUSTRY | PUBLIC HEALTH POLICY | POLICY MAKERS | WAREHOUSES | PHARMACEUTICAL PRICING POLICIES | BUDGETING | POLITICAL CHANGE | ESSENTIAL DRUGS | SERVICE PROVIDERS
eBook
2014, World Bank Study, ISBN 9781464802874, 143
The roots signify the origins and initial steps taken to build a coalition and the associated teething problems; the trunk represents efforts toward sustaining... 
Medical policy | Pharmaceutical policy | Health care reform | Africa, Eastern | Economic development | AUDIENCES | MINISTER | PHARMACY | CIVIL SOCIETY ORGANIZATION | PHARMACEUTICAL SERVICES | HEALTH PROGRAMS | SERVICE DELIVERY | OUTREACH | VILLAGES | WASTE | HEALTH SECTOR | MORBIDITY | SOCIAL MARKETING | ACCESS TO HEALTH SERVICES | PEOPLE WITH DISABILITIES | USER PARTICIPATION | HUMAN DEVELOPMENT | CONSUMERS | PROCUREMENT POLICIES | SUPPLY CHAIN | ASSETS | HEALTH PROMOTION | HEALTH CARE SERVICE DELIVERY | GOOD GOVERNANCE | INJURIES | PHARMACEUTICAL PROCUREMENT | MEDICAL SUPPLIES | GMP | HEALTH SYSTEMS | HUMAN RESOURCES | DATA ANALYSIS | DISTRIBUTION OF PHARMACEUTICALS | HEALTH INFORMATION | ACCOUNTABILITY SYSTEMS | HEALTH SERVICES | PHARMACEUTICAL SUPPLY | CAPACITY DEVELOPMENT | MORTALITY | HEALTH CARE PROVISION | PATIENTS | HEALTH SERVICE DELIVERY | COLLECTIVE ACTIONS | TUBERCULOSIS | CONSENSUS | MEDICAL STORES | CIVIL SOCIETY | PHARMACEUTICAL SUPPLY CHAINS | PATRONAGE | ACCOUNTABILITY | DECISION MAKING | CONTRACT MONITORING | HEALTH POLICY | STAKEHOLDERS | HEALTH CARE SYSTEMS | CHRONIC DISEASES | MEDICAL CARE | CHILD HEALTH | FIGURES | STAKEHOLDER | COMMUNITY HEALTH | CONSENSUS BUILDING | RULE OF LAW | HEALTH OUTCOMES | SELF-INTEREST | WEAK ACCOUNTABILITY | MEDICINES | PHARMACEUTICAL MANUFACTURING | CONSULTATIONS | HEALTH CARE PROVIDERS | DISCLOSURE | QUALITY OF HEALTH | CIVIL SOCIETY ORGANIZATIONS | HUMAN RIGHTS | BRAINSTORMING | ACCESS TO HEALTH | HEALTH ORGANIZATION | HEALTH SYSTEM | FREEDOM OF SPEECH | DATA COLLECTION | SUPPLIERS | COMMUNICABLE DISEASES | INSTITUTIONAL CAPACITY | ENABLING ENVIRONMENT | QUALITY ASSURANCE | HEALTH COSTS | COMMUNITY LEADERS | ILLNESS | PROCUREMENT | ACCESS TO HEALTH CARE SERVICES | BUDGET ADVOCACY | MEDICINE | GRASSROOTS ORGANIZATIONS | EXPENDITURES | INITIATIVE | LOCAL GOVERNMENT | NATIONAL HEALTH INSURANCE | DOCTORS | CIVIL SOCIETY ASSOCIATIONS | CIVIL SOCIETY CAPACITY | CONFIDENCE | PACKAGING | DISTRICT AUTHORITIES | PROCUREMENT LAWS | STANDARD TREATMENT GUIDELINES | HEALTH SERVICE | SOCIAL ACCOUNTABILITY | VIOLENCE | FAMILY PLANNING | INTEGRATION | HEALTH CARE | LAWYERS | HEALTH INFORMATION SYSTEM | LEGAL FRAMEWORK | APPOINTEES | RECONSTRUCTION | LOCAL AUTHORITIES | PHARMACEUTICAL MANUFACTURERS | BUILDING CONSENSUS | CIVIL SOCIETY GROUPS | PHARMACISTS | INSTITUTIONAL STRENGTHENING | CIVIL SOCIETY MONITORING | HUMAN RIGHTS COMMISSION | HEALTH PROVIDERS | LOCAL CAPACITY | MEDICAL SERVICES | EXTREME POVERTY | SOCIAL DEVELOPMENT | WORKERS | QUALITY CONTROL | DEVELOPMENT GOALS | DECENTRALIZATION | HEALTH SYSTEMS RESEARCH | LAWS | PHARMACEUTICAL PRODUCTS | ANTICORRUPTION | PROCUREMENTS | INTEREST GROUPS | LEADERSHIP | HEALTH CARE FINANCING | REMEDY | STAKEHOLDER ANALYSIS | PARLIAMENTARY COMMITTEE | PUBLIC HEALTH | CITIZEN PARTICIPATION | HEALTH REFORMS | CONSULTATION | PUBLIC ADMINISTRATION | AGED | INTERVENTION | HIV/AIDS | BEST PRACTICES | PHARMACEUTICALS | HEALTH CARE REFORMS | LAWYER | PHARMACEUTICAL SYSTEMS | INVENTORY CONTROL | ACCOUNTABILITY MECHANISMS | SUPPLY CHAIN MANAGEMENT | PATIENT | CITIZEN MONITORING | COMMODITIES | SOCIAL SERVICES | SERVICE DELIVERY SYSTEMS | PHARMACEUTICAL | IRRATIONAL USE | MEDICAL DOCTOR | CAPACITY BUILDING | MENTAL HEALTH | REPRODUCTIVE HEALTH | PHARMACEUTICAL SECTOR | GOVERNMENTAL ORGANIZATION | INTERVIEWS | MEDIA | CIVIL SOCIETY ACTORS | HEALTH FINANCING | INTEREST GROUP | BASIC NEEDS | SOCIOECONOMIC DEVELOPMENT | MOBILIZATION | SOCIAL ISSUES | POVERTY REDUCTION | BUDGET ALLOCATION | PROJECT EVALUATION | HEALTH REFORM | IMMUNODEFICIENCY | HEALTH EXPENDITURE | DELIVERY SYSTEMS | GLOBAL ANTICORRUPTION | COMPETENCIES | SOCIAL WELFARE | HEALTH FACILITIES | TRANSPARENCY | COLLABORATION | ACCESS TO INFORMATION | FREEDOM OF INFORMATION | PURCHASING | QUALITY OF LIFE | STRATEGIC PLANNING | POLITICAL ACCOUNTABILITY | PHARMACEUTICAL INDUSTRY | BUSINESS COMMUNITY | DISTRICT COUNCIL | LISTENING | VACCINATION | CIVIL SOCIETY ENGAGEMENT | FACILITATORS | SUSTAINABLE HEALTH CARE | ESSENTIAL DRUGS | SERVICE PROVIDERS | HEALTH CARE COSTS | EXTRACTIVE INDUSTRIES
eBook